Merck remains confident as Keytruda faces loss of exclusivity, projecting growth through expanded indications and robust pipeline advancements, underscoring resilience amid increasing market competition.
Browsing: Merck
Merck commits nearly $2 billion to acquire oral lipid-lowering drug from Chinese biotech firm, aiming to expand its cardiovascular portfolio and enhance global market reach, BioSpace reports.